Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate - chewable tablet - 680 mg/80 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations

Malta - English - Medicines Authority

bayer public limited company 400 south oak way, reading berkshire rg2 6ad, united kingdom - calcium carbonate, magnesium carbonate, heavy - chewable tablet - calcium carbonate 680 mg magnesium carbonate, heavy 80 mg - drugs for acid related disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium carbonate; hyprolose; microcrystalline cellulose; polysorbate 80; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atorvastatin calcium trihydrate, quantity: 86.76 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; calcium carbonate; hyprolose; microcrystalline cellulose; polysorbate 80; croscarmellose sodium; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - calcium carbonate, quantity: 1.25 g - tablet, film coated - excipient ingredients: purified talc; indigo carmine aluminium lake; hyprolose; allura red ac aluminium lake; polysorbate 80; magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; croscarmellose sodium; hypromellose; macrogol 400 - a diet deficient in calcium can lead to osteoporosis in later life. calcium may help prevent osteoporosis when dietary intake is inadequate ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: sodium lauryl sulfate; dibasic sodium phosphate; hypromellose; polydextrose; magnesium stearate; indigo carmine aluminium lake; monobasic sodium phosphate; titanium dioxide; macrogol 8000; croscarmellose sodium; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: hypromellose; magnesium stearate; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcium carbonate, quantity: 1.2492 g (equivalent: calcium, qty 500 mg) - tablet - excipient ingredients: magnesium stearate; hypromellose; sodium lauryl sulfate; dibasic sodium phosphate; monobasic sodium phosphate; titanium dioxide; croscarmellose sodium; macrogol 8000; polydextrose; indigo carmine aluminium lake; pregelatinised maize starch - alendronate/vitamin d3 and calcium composite pack is indicated for the treatment of:,? osteoporosis* in select patients where vitamin d and calcium supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture